DUX4 and facioscapulohumeral muscular dystrophy: ROC curve analysis demonstrated that there was no significant difference between the discriminatory power of our PAX7 biomarker and the DUX4 biomarkers on FSHD patient cell lines (De-Long’s test p > 0.05, Fig. 5e).